Aventis sells Azmacort to Kos for $200m
Franco-German drugmaker Aventis has announced the sale of its Azmacort (triamcinolone acetonide) inhalation aerosol to the USA's Kos Pharmaceuticals. The terms of the agreement state that Kos is to acquire Azmacort for a single cash purchase price of $200 million.
In addition, Kos will pay Aventis a yearly royalty based on net sales following the launch of the new Azmacort HFA (hydrofluoralkane propellant) formulation, which has a substantially lower ozone-depleting effect than its predecessor. Completion of the transaction is expected by the end of the first quarter, pending US regulatory approval under the Hart-Scott-Rodino Improvements Act.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze